Long-acting Injectable Antipsychotics and Stigma: Some Considerations and Future Perspectives-Reference-Cited by-同舟云学术

Long-acting Injectable Antipsychotics and Stigma: Some Considerations and Future Perspectives

Published:2023-04 Issue:13 Volume:29 Page:981-983
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Natale Antimo¹,Fusar-Poli Laura¹²,Amerio Andrea³⁴,Escelsior Andrea³⁴,Serafini Gianluca³⁴,Aguglia Eugenio¹,Amore Mario³⁴,Aguglia Andrea³⁴

Affiliation:

1. Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

2. Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

3. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, Genoa, Italy

4. Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genoa, Italy

Abstract

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference25 articles.

1. Vieta E.; Berk M.; Schulze T.G.; Bipolar disorders. Nat Rev Dis Primers 2018,4(1),18008

2. Correll CU; Using patient-centered assessment in schizophrenia care: Defining recovery and discussing concerns and preferences. J Clin Psychiatry 2020,81(3),MS19053BR2C

3. Emsley R.; Chiliza B.; Asmal L.; Harvey B.H.; The nature of relapse in schizophrenia. BMC Psychiatry 2013,13(1),50

4. Emsley R.; Nuamah I.; Hough D.; Gopal S.; Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012,138(1),29-34

5. Czobor P.; Van Dorn R.A.; Citrome L.; Kahn R.S.; Fleischhacker W.W.; Volavka J.; Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol 2015,25(8),1158-1166